Trending...
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- Mandeville Pests May Pose Serious Health Risks for Your Family
BOSTON, May 20, 2024 ~ Chroma Medicine, Inc. has recently announced the appointment of Jenny Marlowe, Ph.D., as their new Chief Development Officer. Dr. Marlowe brings with her a wealth of experience and expertise in the field of genomic medicine, making her a valuable addition to the company's leadership team.
According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.
Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.
More on Ohio Pen
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.
In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.
Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.
With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.
Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.
More on Ohio Pen
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Ohio State Parks Foundation​ Names Christopher Gillcrist Executive Director
- Cleveland's Puerto Rican Community Takes Center Stage: Inaugural Boricua Block Party Set for Sep 12
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.
In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.
Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.
With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
0 Comments
Latest on Ohio Pen
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Artist and Photographer Joshua C. Terrell Launches New Website Showcasing Work Across Central Ohio
- Joshua Terrell Consulting Highlights the Importance of Business Information When Using AI
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- Lake Norman Philharmonic - Free Community Concert